Andrew Mesecar, Distinguished Professor of Biochemistry and the Walther Professor in Cancer Structural Biology, was named assistant vice president for research and director of the Purdue Institute for Cancer Research after serving, since Aug. 2022, as interim director. Mesecar was chosen for the position after a nationwide search.
At its most recent meeting, the FDA Oncologic Drugs Advisory Committee focused on perioperative clinical trials, which the agency defined as neoadjuvant phase followed by surgery and continuing with adjuvant treatment using the same experimental agent (The Cancer Letter, July 26, 2024).
